Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial

Bahl, A.; Oudard, S.; Tombal, B.; Ozguroglu, MUSTAFA; Hansen, S.; Kocak, I.; Gravis, G.; Devin, J.; Shen, L.; de Bono, J.; Sartor, A.

doi:10.1093/annonc/mdt194

Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial

Bahl A., Oudard S., Tombal B., Ozguroglu M., Hansen S., Kocak I., ...Daha Fazla

ANNALS OF ONCOLOGY, cilt.24, sa.9, ss.2402-2408, 2013 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 24 Sayı: 9
Basım Tarihi: 2013
Doi Numarası: 10.1093/annonc/mdt194
Dergi Adı: ANNALS OF ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.2402-2408
Anahtar Kelimeler: cabazitaxel, symptom relief, palliative care, prostate cancer, treatment response, quality of life, ABIRATERONE ACETATE, CHEMOTHERAPY, MITOXANTRONE, PREDNISONE, PLACEBO
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Cabazitaxel significantly improves overall survival (OS) versus mitoxantrone in patients with metastatic castration-resistant prostate cancer after docetaxel failure. We examined patient survival at 2 years and tumour-related pain with cabazitaxel versus mitoxantrone.